{"id":"W2112524831","doi":"10.1200/jco.2011.39.2993","title":"Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":212,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Lung cancer; Rash; Oncology; Erlotinib Hydrochloride; Hazard ratio; Clinical endpoint; Epidermal growth factor receptor; Phases of clinical research; Gastroenterology; Cancer; Chemotherapy; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001479458,0.0003405639,0.002213754,0.0002473963,0.00008499109,0.00001489967,0.0001983368,0.0004138068,0.000265886],"category_scores_gemma":[0.0009220857,0.0002316833,0.0004071896,0.0003492067,0.0001542648,0.0003066987,0.00004624064,0.001081726,0.00001082128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001438161,"about_ca_system_score_gemma":0.005502919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001962974,"about_ca_topic_score_gemma":0.0003373075,"domain_scores_codex":[0.9954207,0.0004233873,0.002657821,0.0003157351,0.0004943082,0.0006880575],"domain_scores_gemma":[0.9940659,0.001797608,0.002389334,0.0002877174,0.0005985912,0.0008608535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8080894,0.01242564,0.1215598,0.00007881848,0.001257342,0.000261964,0.001663196,0.0002249908,0.00000933465,0.00001131588,0.001202393,0.05321583],"study_design_scores_gemma":[0.8846911,0.05106371,0.04755729,0.000358591,0.003435147,0.00002423629,0.0004353173,0.0001554361,0.00003851036,0.000001988476,0.01198744,0.000251269],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869837,0.000827484,0.00005382377,0.0006304506,0.003131531,0.003655575,0.00002788044,0.0000235523,0.004665958],"genre_scores_gemma":[0.9945612,0.0004565188,0.001694463,0.0005437299,0.001598564,0.0001937361,0.00005722409,0.00005664497,0.0008379395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07660172,"threshold_uncertainty_score":0.9761941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07140800855381599,"score_gpt":0.4732130208390218,"score_spread":0.4018050122852058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}